Literature DB >> 27873228

Hypertension in Chronic Kidney Disease.

Seyed Mehrdad Hamrahian1, Bonita Falkner2.   

Abstract

Hypertension, a global public health problem, is currently the leading factor in the global burden of disease. It is the major modifiable risk factor for heart disease, stroke and kidney failure. Chronic kidney disease (CKD) is both a common cause of hypertension and CKD is also a complication of uncontrolled hypertension. The interaction between hypertension and CKD is complex and increases the risk of adverse cardiovascular and cerebrovascular outcomes. This is particularly significant in the setting of resistant hypertension commonly seen in patient with CKD. The pathophysiology of CKD associated hypertension is multi-factorial with different mechanisms contributing to hypertension. These pathogenic mechanisms include sodium dysregulation, increased sympathetic nervous system and alterations in renin angiotensin aldosterone system activity. Standardized blood pressure (BP) measurement is essential in establishing the diagnosis and management of hypertension in CKD. Use of ambulatory blood pressure monitoring provides an additional assessment of diurnal variation in BP commonly seen in CKD patients. The optimal BP target in the treatment of hypertension in general and CKD population remains a matter of debate and controversial despite recent guidelines and clinical trial data. Medical therapy of patients with CKD associated hypertension can be difficult and challenging. Additional evaluation by a hypertension specialist may be required in the setting of treatment resistant hypertension by excluding pseudo-resistance and treatable secondary causes. Treatment with a combination of antihypertensive drugs, including appropriate diuretic choice, based on estimated glomerular filtration rate, is a key component of hypertension management in CKD patients. In addition to drug treatment non-pharmacological approaches including life style modification, most important of which is dietary salt restriction, should be included in the management of hypertension in CKD patients.

Entities:  

Keywords:  Adults; Ambulatory blood pressure monitoring; Blood pressure; Chronic kidney disease; Hypertension; Masked hypertension; Resistant hypertension; Salt; Sodium; White coat hypertension

Mesh:

Substances:

Year:  2017        PMID: 27873228     DOI: 10.1007/5584_2016_84

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  37 in total

Review 1.  ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.

Authors:  Andrew M South; Tammy M Brady; Joseph T Flynn
Journal:  Hypertension       Date:  2020-05-05       Impact factor: 10.190

2.  Antihypertensive Treatment in Kidney Transplant Recipients-A Current Single Center Experience.

Authors:  Ulrich Jehn; Katharina Schütte-Nütgen; Markus Strauss; Jan Kunert; Hermann Pavenstädt; Gerold Thölking; Barbara Suwelack; Stefan Reuter
Journal:  J Clin Med       Date:  2020-12-07       Impact factor: 4.241

3.  HDL and Kidney Diseases.

Authors:  Huanhuan Cao; Xia Meng
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

4.  Cardiovascular Risk Stratification and Appropriate Use of Statins in Patients with Chronic Kidney Disease According to Different Strategies.

Authors:  Leandro Barbagelata; Walter Masson; Emiliano Rossi; Martin Lee; Juan Lagoria; Manuel Vilas; Rodolfo Pizarro; Guillermo Rosa Diez
Journal:  High Blood Press Cardiovasc Prev       Date:  2022-06-25

5.  Nocturnal Hypertension in Children With Chronic Kidney Disease Is Common and Associated With Progression to Kidney Replacement Therapy.

Authors:  Monica L Guzman-Limon; Shuai Jiang; Derek Ng; Joseph T Flynn; Bradley Warady; Susan L Furth; Joshua A Samuels
Journal:  Hypertension       Date:  2022-08-18       Impact factor: 9.897

Review 6.  Time-efficient, high-resistance inspiratory muscle strength training for cardiovascular aging.

Authors:  Daniel H Craighead; Kaitlin A Freeberg; Narissa P McCarty; Douglas R Seals
Journal:  Exp Gerontol       Date:  2021-08-10       Impact factor: 4.253

7.  Role of aspirin activated nitric oxide synthase in controlling DOCA-salt-induced hypertension in rats through the stimulation of renal r-cortexin in kidney cortex cells.

Authors:  Uttam Kumar Maji; Tamal Kanti Ghosh; Mitali Chatterjee; Suman Bhattacharya; Sarbashri Bank; Pradipta Jana
Journal:  Int J Health Sci (Qassim)       Date:  2022 Jul-Aug

8.  Antihypertensive therapy prescribing patterns and correlates of blood pressure control among hypertensive patients with chronic kidney disease.

Authors:  Oyunbileg Magvanjav; Rhonda M Cooper-DeHoff; Caitrin W McDonough; Yan Gong; Mark S Segal; William R Hogan; Julie A Johnson
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-11-14       Impact factor: 3.738

9.  Cause of postoperative mortality in patients with end-stage renal disease.

Authors:  Sanghoon Song; Chaeyeon Cho; Sun Young Park; Ho Bum Cho; Jae Hwa Yoo; Mun Gyu Kim; Ji Won Chung; Sang Ho Kim
Journal:  Anesth Pain Med (Seoul)       Date:  2022-02-25

10.  The efficacy of probiotic preparations on inflammatory cytokines in patients with chronic kidney disease: A protocol for systematic review and meta-analysis.

Authors:  Peidong Wang; Yanyan Peng; Yueqin Guo; Yongqiang Zhao
Journal:  Medicine (Baltimore)       Date:  2021-07-02       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.